Randomized Clinical Trial to Evaluate Safety and Efficacy of Innovative Medical Devices for Colostomy Patients

Sponsor
Hydrumedical (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05466721
Collaborator
(none)
50
2
2
4.1
25
6.1

Study Details

Study Description

Brief Summary

The surgical ostomy process happens when it is necessary to open an organ (such as the intestine) in order to maintain a communication channel with the external environment. The need for ostomy surgery can happen as a result of illness, genetic factors, or trauma. Despite the extensive improvements in colorectal surgery, in case there is a need for total or partial extraction and exteriorization of the large intestine (colostomy), it is often necessary to perform a stoma that connects the end of the preserved intestine to the skin, in which cases it is necessary to place a a colostomy bag for stool collection. Thus, there is a substantial number of patients who need to live with a permanent abdominal stoma that significantly affects their quality of life, implying significant changes, both physical and social. It will then be necessary for patients to adjust their daily routines in order to deal with stoma care.

The primary objective of this study is to evaluate the Hydrustoma C3 medical devices (plate C3, capsule C3, night bag C3) in terms of its efficacy and safety as colostomy devices. It is also a primary objective of this study to compare the health-related quality of life in patients with colostomy when using a control and Hydrustoma C3 devices.

Condition or Disease Intervention/Treatment Phase
  • Device: Hydrustoma C3
  • Device: Control device
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
HydrustomaC3 - Randomized Clinical Trial to Evaluate Safety and Efficacy of Innovative Medical Devices for Colostomy Patients
Actual Study Start Date :
Jun 13, 2022
Anticipated Primary Completion Date :
Oct 15, 2022
Anticipated Study Completion Date :
Oct 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Other: Hydrustoma C3 - Control Device

The participant will use the Hydrustoma C3 devices for 14 days and then switch into the control device for another 14 days.

Device: Hydrustoma C3
The participant will use the device for 14 days.

Device: Control device
The participant will use the device for 14 days.
Other Names:
  • Coloplast Alterna
  • Other: Control Device - Hydrustoma C3

    The participant will use the control devices for 14 days and then switch into the Hydrustoma C3 devices for another 14 days.

    Device: Hydrustoma C3
    The participant will use the device for 14 days.

    Device: Control device
    The participant will use the device for 14 days.
    Other Names:
  • Coloplast Alterna
  • Outcome Measures

    Primary Outcome Measures

    1. Efficacy of the device (journal of capsule/bag changes) [14 days]

      Efficacy will be accessed by asking patients to record on a journal/diary, for each capsule/bag change, what was the reason for the change, and the occurrence and level of leakage.

    2. Quality of life of the participant (Stoma Quality of Life questionnaire) [14 days]

      In order to compare stoma related quality of life in patients with colostomy when using a control device and the Hydrustoma C3 devices the Stoma Quality of Life questionnaire will be used. This questionnaire is composed of 20 questions. Example of question "I worry that the bag detaches.". All questions must be answered on a scale of 1 to 4, being 1 always and 4 never.

    3. Adverse effects [14 days]

      Safety evaluations will be done by monitoring adverse events.

    4. Safety of the device (Discolouration, Erosion, Tissue overgrowth score) [14 days]

      Safety evaluations will be done by monitoring the peristomal skin using the validated Ostomy Skin tool (DET score). The DET Score is calculated by examining the peristomal skin and evaluate the skin based on the descriptions in each of the 3 domains, discolouration (D), erosion (E) and tissue overgrowth (T); and assessing the size of the area affected in each of the 3 domains. The total score is (maximum 15) calculated by adding all of the subscores from each domain together.

    Secondary Outcome Measures

    1. Satisfaction of the participant (questionnaire) [14 days]

      The patients will be asked to evaluate the medical device in terms of application, discretion of the device, stoma related noise, feelings of security (confidence) and overall satisfaction of use (including comfort and impact on body image). The questionnaire has 8 questions of multiple choice (example "Regarding the safety during usage of the devices, I feel: (1) very insecure; (2) moderately insecure; (3) Moderadately secure; (4) Very secure") and 1 open answer question.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Written informed consent;

    • Male and Female patients;

    • Adult aged ≥ 18;

    • Descending and sigmoid colostomy created more than 3 months previously to the beginning of the study;

    • Having formed stool and using a flat ostomy appliance;

    • Able to understand the study procedures and fill questionaries;

    • Able to apply and remove the ostomy device autonomously.

    Exclusion Criteria:
    • Repeated experiences of leakage with the usual ostomy device,

    • Chronically liquid stools,

    • Peristomal skin disorders,

    • Known allergic reactions to components of the device,

    • Receiving chemotherapy, radiation therapy or steroids in the previous month

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital Da Senhora Da Oliveira - Guimarães Guimarães Braga Portugal 4835
    2 Hospital de Braga Braga Portugal 4710

    Sponsors and Collaborators

    • Hydrumedical

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hydrumedical
    ClinicalTrials.gov Identifier:
    NCT05466721
    Other Study ID Numbers:
    • Hydrustoma C3
    First Posted:
    Jul 20, 2022
    Last Update Posted:
    Jul 20, 2022
    Last Verified:
    Jul 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Jul 20, 2022